Related Experiment Video
Updated: Aug 30, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.5K
Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral
Gregory Y H Lip1,2, Richard R Murphy3, Farhad Sahiar3
1Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
JAMA Network Open
|August 31, 2022
Summary
The CHA2DS2-VASc score effectively predicts stroke and bleeding risk in nonvalvular atrial fibrillation patients on oral anticoagulants. Higher scores correlate with increased adverse event incidence, informing clinical decisions.
Area of Science:
- Cardiology
- Pharmacology
- Epidemiology
Background:
- The CHA2DS2-VASc score is standard for assessing stroke risk in nonvalvular atrial fibrillation (NVAF).
- Comprehensive evaluation of safety and effectiveness outcomes by independent, categorical risk strata is lacking.
Purpose of the Study:
- To evaluate adverse outcomes in NVAF patients receiving oral anticoagulants.
- Stratify outcomes by CHA2DS2-VASc risk score, thromboembolic history, and age group.
Main Methods:
- Retrospective cohort study using 5 large health claims databases (January 2012-June 2019).
- Analysis of over 1.1 million adult NVAF patients initiating oral anticoagulants.
- Stratification by CHA2DS2-VASc score, thromboembolic event history, and age group.
Main Results:
- Incidence of stroke, systemic embolism, and major bleeding increased with higher CHA2DS2-VASc scores.
- Patients in higher risk strata showed progressively higher event rates and cumulative incidences.
- Thromboembolic event history significantly impacted stroke incidence within risk strata.
Conclusions:
- Observed event incidences align with expected trends based on risk stratification.
- Findings highlight the importance of CHA2DS2-VASc score, event history, and age in predicting outcomes.
- Results can inform clinical decision-making, research, and policy for NVAF management.
More Related Videos
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
863
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
863
01:29Venous Thrombosis III: Interprofessional Care
18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
163
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
163
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
619
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
619
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K